natgillin/translations-raw huggingface dataset:
The analysis of all recorded incremental recoveries in previously treated patients demonstrated a median rise of &gt; 2% ( &gt; 2 IU/dL) per IU/kg body weight for Kovaltry.
Analiza svih zabilježenih prirasta po jedinici doze u prethodno liječenih bolesnika pokazala je da prilikom korištenja lijeka Kovaltry dolazi do medijana porasta od &gt; 2% ( &gt; 2 IU/dl) po IU/kg tjelesne težine.
The analysis of patients who achieved mitotane levels ≥ 14 mg/l at least once in 6 six months versus patients who mitotane levels were &lt; 14 mg/l could suggest that patients with mitotane plasma levels ≥ 14 mg/l could have an improvement in disease control rate (62.9% versus 33.5%; p &lt; 0.
Analiza bolesnika koji su barem jednom u 6 mjeseci dostigli razinu mitotana od ≥ 14 mg/l u odnosu na bolesnike kod kojih su razine mitotana bile &lt; 14 mg/l može upućivati kako je kod bolesnika s razinama mitotana u plazmi ≥ 14 mg/l moglo doći do poboljšanja u stopi kontrole bolesti (62,9% naspram 33,5%; p &lt; 0.
The analysis per cycle performed in these patients showed thrombocytopenia of grade 3 and 4 in approximately 3% and &lt; 1% of cycles respectively.
Analiza izvršena po ciklusu u tih bolesnika pokazala je trombocitopeniju 3. i 4. stupnja u približno 3 % odnosno &lt; 1 % ciklusa.
The anti-HA antibody responses in healthy subjects aged &gt; 60 years who received either one or two doses of 0.5 ml 21 days apart were as follows:
Odgovor anti-HA antitijela u zdravih ispitanika u dobi &gt; 60 godina koji su primili ili jednu ili dvije doze od 0,5 ml, u razmaku od 21 dan, bio je sljedeći:
The antigen is expressed on 95 % of all B cell non-Hodgkin’s lymphomas.
Antigen je izražen u &gt; 95% svih B-staničnih ne-Hodgkinovih limfoma.
The antimicrobial activity of ceftazidime against specific pathogens has been shown to best correlate with the percent time of free-drug concentration above the ceftazidime/avibactam minimum inhibitory concentration over the dose interval (%fT &gt; MIC of ceftazidime/avibactam).
Pokazalo se da antimikrobna aktivnost ceftazidima protiv specifičnih patogena najbolje korelira s postotkom vremena tijekom intervala doziranja u kojem je koncentracija nevezanog lijeka iznad minimalne inhibitorne koncentracije ceftazidima/avibaktama (%fT &gt; MIK ceftazidima/avibaktama).
The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine &gt; 1.5 mg/dL and 2.0 mg/dL).
U ispitivanju APEX procjenjivana je djelotvornost kod 40 bolesnika s oštećenom funkcijom bubrega (tj. početna razina kreatinina u serumu &gt; 1,5 mg/dl i ≤2,0 mg/dl).
The AUC is 50% higher in elderly ( &gt; 65 years) than in young subjects.
AUC je 50% viši u starijih osoba ( &gt; 65 godina) nego u mladih ispitanika.
The AUC is 50% higher in elderly ( &gt; 65 years) than in young subjects.
AUC je 50% viši u starijih ( &gt; 65 godina) nego u mladih ispitanika.
The average differences between aliskiren and placebo for the low and mid dose groups were &lt; 0.2 mmHg.
Prosječna razlika između aliskirena i placeba za skupine s niskom i srednjom dozom bila je &lt; 0,2 mmHg.
The average improvement over three years for salmeterol/fluticasone propionate compared with placebo was -3.1 units (95% CI: -4.1 to -2.1; p &lt; 0.001) and when compared with salmeterol was -2.2 units (p &lt; 0.001) and when compared with FP was -1.2 units (p=0.017).
Prosječno poboljšanje tijekom tri godine uzimanja salmeterola/flutikazonpropionata u usporedbi s placebom iznosilo je -3,1 jedinice (95% CI: -4,1 do -2,1; p &lt; 0,001), i u usporedbi sa salmeterolom iznosilo je -2,2 jedinice (p &lt; 0,001), a u usporedbi s FP-om iznosilo je -1,2 jedinica (p=0,017).
The B cell tumours include CLL (generally associated with lower levels of CD20 expression) and non-Hodgkin's lymphomas (where &gt; 90% tumours have high levels of CD20 expression).
B-stanični tumori uključuju KLL (općenito povezana s nižom razinom ekspresije CD20) i non- Hodgkinove limfome (pri čemu &gt; 90% tumora ima visoke razine ekspresije CD20).
The BALLR1 study, also evaluating the effects of iNO in preterm neonates, but initiating iNO at 7 days and in a dose of 20 ppm, found a significant increase in neonates alive without BPD at gestational week 36, 121 (45 % vs.
Ispitivanje BALLR1, koje se također bavilo učincima iNO u nedonoščadi, ali je iNO uveden nakon 7 dana u dozi od 20 ppm, utvrdilo je značajno povećanje u preživjele novorođenčadi bez BPD-a u 36. tjednu gestacije, 121 (45% naspram 95 (35,4%) p &lt; 0,028.
The BALLR1 study, also evaluating the effects of iNO in preterm neonates, but initiating iNO at 7 days and in a dose of 20 ppm, found a significant increase in neonates alive without BPD at gestational week 36, 121 (45 % vs.
Ispitivanje BALLR1, koje se također bavilo učincima iNO u nedonoščadi, ali je iNO uveden nakon 7 dana u dozi od 20 ppm, utvrdilo je značajno povećanje u preživjele novorođenčadi bez BPD-a u 36. tjednu gestacije, 121 (45%) naspram 95 (35,4%) p &lt; 0,028.
The basis for this analysis was that at least 100 patients ( &gt; 5% of the studied population) were treated concomitantly with these medicinal products for at least 90% of the study period.
Temelj analize bio je da je barem 100 bolesnika ( &gt; 5% ispitivane populacije) istovremeno liječeno s tim lijekovima tijekom barem 90% vremena ispitivanja.
The benefits and risks of &gt; 2 treatment courses have not been fully established, but results suggest that the safety profile does not appear to change with additional courses.
Koristi i rizici &gt; 2 ciklusa liječenja nisu u potpunosti utvrđeni, no rezultati ukazuju na to da dodatni ciklusi ne mijenjaju profil sigurnosti.
The binding of eslicarbazepine to plasma proteins is relatively low ( &lt; 40%) and independent from concentration.
Vezanje eslikarbazepina za proteine plazme relativno je nisko ( &lt; 40%) i neovisno o koncentraciji.
The bioavailability of gamithromycin was &gt; 92 %.
Biodostupnost VMP bila je &gt; 92%.
The bioavailability of sarolaner following oral dosing was high at &gt; 85%.
Biološka raspoloživost sarolanera nakon peroralne primjene visoka je &gt; 85%.
The bioavailability of the compound was &gt; 98 % with no gender differences.
Biodostupnost sastojaka je bila &gt; 98 % bez obzira na spol.
The blood pressure lowering effects of two doses of telmisartan were assessed in 76 hypertensive, largely overweight patients aged 6 to &lt; 18 years (body weight ≥ 20 kg and ≤ 120 kg, mean 74.6 kg), after taking telmisartan 1 mg/kg (n = 29 treated) or 2 mg/kg (n = 31 treated) over a four-week treatment period.
Učinci primjene dvije doze telmisartana na snižavanje krvnog tlaka procijenjeni su u 76 uglavnom pretilih bolesnika s hipertenzijom, u dobi od 6 do &lt; 18 godina (tjelesna težina ≥ 20 kg i ≤ 120 kg, u prosjeku 74,6 kg), nakon uzimanja telmisartana 1 mg/kg (n = 29 liječenih) ili 2 mg/kg (n = 31 liječena) tijekom razdoblja liječenja od četiri tjedna.
The blood pressure lowering effects of two doses of telmisartan were assessed in 76 hypertensive, largely overweight patients aged 6 to &lt; 18 years (body weight ≥ 20 kg and ≤ 120 kg, mean 74.6 kg), after taking telmisartan 1 mg/kg (n = 29 treated) or 2 mg/kg (n = 31 treated) over a four-week treatment period.
Učinci snižavanja krvnog tlaka dviju doza telmisartana ocjenjivani su na 76 hipertenzivnih bolesnika s uvelike pretjeranom težinom u dobi od 6 do &lt; 18 godina (tjelesna težina ≥ 20 kg i ≤ 120 kg, srednja vrijednost 74,6 kg), nakon uzimanja telmisartana 1 mg/kg (n = 29 liječenih) ili 2 mg/kg (n = 31 liječenih) tijekom četverotjednog razdoblja liječenja.
The blood pressure lowering effects of two doses of telmisartan were assessed in 76 hypertensive, largely overweight patients aged 6 to &lt; 18 years (body weight ≥ 20 kg and ≤ 120 kg, mean 74.6 kg), after taking telmisartan 1 mg/kg (n = 29 treated) or 2 mg/kg (n = 31 treated) over a four-week treatment period.
Učinci snižavanja krvnog tlaka dviju doza telmisartana ocjenjivani su na 76 hipertenzivnih bolesnika suvelike pretjeranom težinom u dobi 6 do &lt; 18 godina (tjelesna težina ≥ 20 kg i ≤ 120 kg, prosjek 74,6 kg), nakon uzimanja telmisartana 1 mg/kg (n = 29 liječenih) ili 2 mg/kg (n = 31 liječenih) tijekom četverotjednog razdoblja liječenja.
The bolus volume should be administered rapidly ( &lt; 1 minute), from the diluted bag via manual intravenous push or pump.
Volumen bolusa se mora primijeniti brzo ( &lt; 1 minute), iz razrijeđene vrećice ručno brzom intravenskom injekcijom ili pumpom.
The breakpoints for reduced efficacy with etravirine ( &gt; 2 etravirine-associated mutations at baseline, see clinical results section) applies when etravirine is given in combination with a boosted protease inhibitor.
Točka promjene u kojoj se smanjuje djelotvornost etravirina ( &gt; 2 mutacije povezane s etravirinom na početku liječenja, vidjeti dio s kliničkim rezultatima) primjenjiva je kada se etravirin daje u kombinaciji s pojačanim inhibitorima proteaze.
The calculation of the required dose of factor IX is based on the empirical finding that 1 International Unit (IU) factor IX per kg body weight is expected to increase the circulating level of factor IX by an average of 1.3 IU/dl (1.3 % of normal) in patients ≥ 12 years of age and by 1.0 IU/dl (1.0 % of normal) in patients &lt; 12 years of age.
Izračun potrebne doze faktora IX temelji se na empirijskom saznanju da 1 internacionalna jedinica (IU) faktora IX po kg tjelesne težine očekivano povećava cirkulirajuću razinu faktora IX u plazmi za prosječno 1,3 IU/dl (1,3% normalne vrijednosti) u bolesnika u dobi ≥ 12 godina odnosno za 1,0 IU/dl (1,0% normalne vrijednosti) u bolesnika u dobi &lt; 12 godina.
The calculation of the required dose of factor IX is based on the empirical finding that 1 International Unit (IU) factor IX per kg body weight is expected to increase the circulating level of factor IX by an average of 1.3 IU/dl (1.3 % of normal) in patients ≥ 12 years of age and by 1.0 IU/dl (1.0 % of normal) in patients &lt; 12 years of age.
Izračun potrebne doze faktora IX temelji se na empirijskom saznanju da 1 internacionalna jedinica (IU) faktora IX po kg tjelesne težine očekivano povećava cirkulirajuću razinu faktora IX u plazmi za prosječno 1,3 IU/dl (1,3% normalne vrijednosti) u bolesnika u dobi ≥ 12 godina, odnosno za 1,0 IU/dl (1,0% normalne vrijednosti) u bolesnika u dobi &lt; 12 godina.
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction ( &lt; 35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Studija CAPRIE uključivala je 19 185 bolesnika s aterotrombozom koja se manifestirala kao nedavni infarkt miokarda ( &lt; 35 dana), nedavni ishemijski moždani udar (između 7 dana i 6 mjeseci) ili utvrđena bolest perifernih arterija (BPA).
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction ( &lt; 35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Studija CAPRIE uključivala je 19 185 bolesnika s aterotrombozom koje se manifestirala kao nedavni infarkt miokarda ( &lt; 35 dana), nedavni ishemijski moždani udar (između 7 dana i 6 mjeseci) ili utvrđena bolest perifernih arterija (BPA).
The capsule shell consists of gelatin, sorbitol special-glycerine blend (glycerin, sorbitol, sorbitol anhydrides (1,4-sorbitan), mannitol and water), titanium dioxide (E171) and printing ink (SDA 35A alcohol (ethanol &amp; ethyl acetate), propylene glycol (E1520), iron oxide black (E172), polyvinyl acetate phthalate, purified water, isopropyl alcohol, macrogol 400, ammonium hydroxide 28%)
Ovojnica kapsule sastoji se od želatine, smjese sorbitola i glicerola (glicerol, sorbitol, sorbitol bezvodni (1,4-sorbitan), manitol i voda), titanijev dioksid (E171) i tinta za označavanje (SDA 35A alkohol (etanol &amp; etilacetat), propilenglikol (E1520), željezov oksid crni (E172), poli(vinilacetat)ftalat, pročišćena voda, izopropilni alkohol, makrogol 400, amonijev hidroksid 28%).
The central tendency analysis indicated that all upper limits of the 90% CI for the LS mean change from Baseline in QTcF at all Cycle 2 Day 1 time points were &lt; 20 msec.
Analiza središnje tendencije pokazala je da su sve gornje granice 90%-tnog CI za srednju vrijednost promjene dobivenu metodom najmanjih kvadrata u odnosu na početne vrijednosti QTcF-intervala u svim vremenskim točkama 1. dana 2. ciklusa bile &lt; 20 msek.
The change from baseline to Month 18 in LVMi (g/m2) in patients with left ventricular hypertrophy (females with baseline LVMi &gt; 95 g/m2 and males with baseline LVMi &gt; 115 g/m2) was -8.4 (95% CI: -15.7, 2.6; n=13) for migalastat and 4.5 (95% CI: -10.7, 18.4; n=5) for ERT.
Promjena LVMi (g/m2) od početne vrijednosti do 18. mjeseca u bolesnika s hipertrofijom lijevog ventrikula (ženski bolesnici s početnom vrijednošću LVMi &gt; 95 g/m2 te muški bolesnici s početnom vrijednošću LVMi &gt; 115 g/m2) iznosila je –8,4 (95 % CI: –15,7; 2,6; n = 13) za migalastat i 4,5 (95 % CI: -10,7; 18,4; n = 5) za ERT.
The clinical benefit of YENTREVE compared with placebo has not been demonstrated in women with mild SUI, defined in randomised trials as those with IEF &lt; 14 per week.
Klinička korist lijeka YENTREVE u usporedbi s placebom nije pokazana u žena s blagom SUI, koje su u randomiziranim ispitivanjima definirane kao bolesnice s &lt; 14 UEI na tjedan.
The clinical data available suggest that those patients whose initial haemoglobin is very low ( &lt; 6 g/dl or &lt; 3.75 mmol/l) may require higher maintenance doses than those whose initial anaemia is less severe (Hb &gt; 8 g/dl or &gt; 5 mmol/l).
Dostupni klinički podaci pokazuju da bolesnici s vrlo niskim početnim vrijednostima hemoglobina ( &lt; 6 g/dl ili &lt; 3,75 mmol/l) mogu zahtijevati veće doze održavanja nego oni kod kojih je početna anemija manje izražena (Hb &gt; 8 g/dl ili &gt; 5 mmol/l).
The clinical data available suggest that those patients whose initial haemoglobin is very low ( &lt; 6 g/dl or &lt; 3.75 mmol/l) may require higher maintenance doses than those whose initial anaemia is less severe (Hb &gt; 8 g/dl or &gt; 5 mmol/l).
Dostupni klinički podaci pokazuju da bolesnici s vrlo niskim početnim vrijednostima hemoglobina ( &lt; 6 g/dl ili &lt; 3,75 mmol/l) mogu zahtijevati veće doze održavanja nego oni kod kojih je početna anemija manje teška (Hb &gt; 8 g/dl ili &gt; 5 mmol/l).
The clinical data available suggest that those patients whose initial haemoglobin is very low ( &lt; 6.8 g/dl or &lt; 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher &gt; 6.8 g/dl or &gt; 4.25 mmol/l).
Dostupni klinički podaci pokazuju da bolesnici čije su početne vrijednosti hemoglobina vrlo niske ( &lt; 6,8 g/dl ili &lt; 4,25 mmol/l), mogu zahtijevati veće doze održavanja u odnosu na bolesnike s višim početnim vrijednostima hemoglobina ( &gt; 6,8 g/dl ili 4,25 mmol/l).
The clinical efficacy of caffeine citrate was assessed in a multicentre, randomised, double-blind study that compared caffeine citrate to placebo in 85 preterm infants (gestational age 28 to &lt; 33 weeks) with apnoea of prematurity.
Klinička djelotvornost kofeincitrata procijenila se u multicentričnom, randomiziranom, dvostruko slijepom ispitivanju u kojem se kofeincitrat uspoređivao s placebom u 85-ero nedonoščadi (gestacijska dob 28 do &lt; 33 tjedna) s apnejom nedonoščeta.
The clinical experience in patients &gt; 75 years is very limited (see section 5.2).
Kliničko iskustvo u bolesnika starijih od 75 godina je vrlo oskudno (vidjeti dio 5.2).
The clinical experience in patients &gt; 75 years is very limited.
Kliničko iskustvo primjene u bolesnika starijih od 75 godina vrlo je oskudno.
The clinical studies have been conducted in a patient population with a mean age &gt; 65 years.
Klinička ispitivanja provedena su na populaciji bolesnika prosječne dobi &gt; 65 godina.
The clinical studies have been conducted in a patient population with a mean age &gt; 65 years.
Klinička ispitivanja provedena su na populaciji bolesnika prosječne dobi ≥ 65 godina.
The Cmax, AUC and elimination half-life of brimonidine are similar in elderly ( &gt; 65 years of age) subjects compared to young adults.
Cmax, AUC i poluvijek eliminacije brimonidina u starijih osoba ( &gt; 65 godina starosti) slični su onima u mladih odraslih osoba.
The co-primary endpoints were the proportion of patients in clinical remission (CDAI &lt; 150) at week 30 and time to loss of response through week 54.
Dvije primarne mjere ishoda bile su udio bolesnika u kliničkoj remisiji (CDAI &lt; 150) u 30. tjednu i vrijeme do gubitka odgovora do 54. tjedna.
The co-primary safety endpoints were discontinuation due to an adverse event and confirmed increase in serum creatinine ≥ 0.5 mg/dl or confirmed serum phosphate of &lt; 2 mg/dl.
Ko-primarne mjere ishoda za sigurnost bile su prekid liječenja zbog nuspojave i potvrđenog porasta kreatinina u serumu za ≥ 0,5 mg/dl ili potvrđeni fosfat u serumu &lt; 2 mg/dl.
The co-primary safety endpoints were discontinuation due to an adverse event and confirmed increase in serum creatinine ≥ 0.5 mg/dl or confirmed serum phosphate of &lt; 2 mg/dl.
Ko-primarne mjere ishoda za sigurnost bile su prekid liječenja zbog nuspojave i potvrđenog porasta kreatinina u serumu za ≥ 0.5 mg/dl ili potvrđeni fosfat u serumu &lt; 2 mg/dl.
The combination of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) and is not recommended in other patients (see sections 4.3, 4.4).
Kombinacija telmisartana s aliskirenom je kontraindicirana kod bolesnika s dijabetes melitusom ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) te se ne preporučuje kod drugih bolesnika (vidjeti dijelove 4.3, 4.4).
The concomitant administration of CRESEMBA and high doses of ritonavir ( &gt; 200 mg every 12 hours) is contraindicated.
Istodobna primjena lijeka CRESEMBA i visokih doza ritonavira ( &gt; 200 mg svakih 12 sati) je kontraindicirana.
The concomitant use of Actelsar HCT with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Actelsar HCT s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Aprovel with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Aprovel s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Edarbi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 mL/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena Edarbija s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR &lt; 60 ml/min/1.73 m2) (see section 4.3).
Istodobna primjena Entresta i lijekova koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolesti ili u bolesnika s oštećenjem bubrega (eGFR &lt; 60 ml/min/1,73 m2) (vidjeti dio 4.3).
The concomitant use of Ifirmacombi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1)
Istodobna primjena Ifirmacombi s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The concomitant use of Ifirmasta with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Ifirmaste s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Ipreziv with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 mL/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena Ipreziv s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesaratn Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesartan Hydrochlorothiazide Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73 m²) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Hydrochlorothiazide Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Teva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The concomitant use of Irbesartan Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesartan Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1)
Istodobna primjena lijeka Irbesartan/Hidroklorotiazid Teva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan/Hidroklorotiazid Teva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)